Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.

The goal of ST-segment elevation myocardial infarction (STEMI) management is rapid and sustained reperfusion of the infarct-related artery (1–3). Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method if it can be performed promptly and by an experienced operator (4). Despite widespread improvements in clinical pathways to improve door-to-balloon time and the development of novel antiplatelet and antithrombotic agents and subsequent improved clinical outcomes, STEMI remains a cause of considerable morbidity and mortality (5). As such, numerous pharmacologic and device-based strategies have been developed with the aim of improving outcomes among STEMI patients.